Psoriasis Market

 Market Overview:

The psoriasis market reached a value of US$ 19.2 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2023. Looking forward, IMARC Group expects the top 7 markets to reach US$ 35.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.85% during 2024-2034.

The psoriasis market has been comprehensively analyzed in IMARC's new report titled "Psoriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Psoriasis refers to a chronic, immune-mediated disease in which skin cells build up and develop scales and itchy, dry patches. This condition mainly occurs due to an overactive immune system, which speeds up the growth of skin tissues and causes inflammation. Although psoriasis can appear anywhere on the body, the most common sites are the elbows, knees, scalp, genitals, nails, and lower back. Individuals suffering from the ailment may experience a skin rash, dryness, fissures, peeling, flakiness, small bumps, redness, thickness, pain in the joints, etc. The other common indications include itching, joint stiffness, inflamed tendons, plaque, minor dents, along with discoloration of the nails. Diagnosing the disorder is typically based on a review of the patient's symptoms, medical history, and physical examination. In some cases, a skin biopsy is required to rule out any possible health conditions. This approach utilizes a tiny sample of the affected skin tissue and its investigation under a microscope. The other frequently used tests involve erythrocyte sedimentation rate, laboratory studies, X-rays, etc.

The rising cases of autoimmune disorders, which cause the body's defense system to attack healthy cells by defect, are primarily driving the psoriasis market. Additionally, the increasing prevalence of various triggering factors, such as stress, infections, skin injuries, smoking, excessive alcohol consumption, etc., is also propelling the market growth. Besides this, the widespread adoption of topical medications, including corticosteroids, vitamin D analogs, retinoids, etc., for reducing inflammation and relieving itching and scaling is creating a positive outlook for the market. Moreover, the emerging popularity of TNF-alpha and interleukin inhibitors to help relieve symptoms associated with the ailment is acting as another significant growth-inducing factor. Apart from this, the rising usage of light therapy, which involves shining ultraviolet light on the skin to slow down the overproduction of skin cells and reduce the itchiness, size, and appearance of plaques, is also augmenting the market growth. Furthermore, the escalating demand for dermoscopy, a non-invasive imaging technique that helps identify characteristic features of the ailment and distinguish it from other skin conditions, is expected to drive the psoriasis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the psoriasis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for psoriasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the psoriasis market in any manner.

Recent Developments:

• In March 2024, Boehringer Ingelheim announced the expanded U.S. FDA clearance of its spesolimab-sbzo (Spevigo) injection for the management of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and above weighing ≥40 kg. Spesolimab-sbzo is a humanized selective IgG1 antibody that works by targeting the interleukin-36 receptor (IL-36R).
• In October 2023, a study titled "Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin" by researchers at Wellcome Sanger Institute and collaborators revealed that psoriasis is not caused or spread by spontaneous genetic mutations in the skin.
• In October 2023, Dermavant Sciences, Inc., presented positive results from a phase 4 open-label trial of VTAMA® (tapinarof) cream, 1%, for treating intertriginous plaque psoriasis in adults. The results demonstrated that VTAMA cream can improve plaques, address visible lesions, and improve patients' quality of life.
• In October 2023, Arcutis Biotherapeutics, Inc. announced that the U.S. FDA had approved the supplemental new drug application (sNDA) to broaden the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of psoriasis, including intertriginous areas, to children ages 6 to 11. ZORYVE is a selective PDE4 inhibitor that is effective, safe, and well-tolerated to simplify the management of plaque psoriasis.
• In August 2023, Lihi Eder et al. developed a risk prediction model (PRESTO) for the development of psoriatic arthritis among individuals with psoriasis. PRESTO can also be used to identify people with psoriasis who could benefit from early therapy, as well as to educate them about the risk of psoriatic arthritis.

Key Highlights:

• According to the World Psoriasis Day consortium, psoriasis affects 125 million individuals worldwide, about 2 to 3 percent of the overall population.
• More than 8 million people in the U.S. have psoriasis.
• An estimated 30% of persons with psoriasis develop psoriatic arthritis.
• The frequency of psoriasis in African Americans is 1.5 percent, compared to 3.6 percent among Caucasians.
• The incidence of psoriasis in children escalated with age, from 13.5 per 100,000 person-years (0-3 years old) to 53.1 per 100,000 person-years (14-18 years old).

Drugs:

Duobrii is a combination of halobetasol propionate (HP), a corticosteroid, and tazarotene (TAZ), a retinoid prodrug that is specifically indicated for the topical treatment of plaque psoriasis in adults. This therapeutic agent is supplied as a lotion for topical administration. The combination of HP and TAZ allows for dual mechanistic action in treating psoriasis; HP, a topical corticosteroid, provides a primarily anti-inflammatory effect, and TAZ, a vitamin A derivative, impairs keratinocyte proliferation.

Sonelokimab (M1095) is an investigational anti-IL-17 A/F Nanobody® that neutralizes both IL-17F and IL-17A in patients suffering from moderate to severe chronic plaque-type psoriasis. This drug candidate was developed using nanobody technology. M1095 is administered subcutaneously to individuals suffering from psoriasis.

MP1032 is a drug developed by MetrioPharm that is currently being investigated for its potential in treating psoriasis. It's a small molecule that can modulate the oxidative stress-mediated activation state of macrophages by targeting the immune system and inflammation, which are key factors in the development of psoriasis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the psoriasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the psoriasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current psoriasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the psoriasis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the psoriasis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the psoriasis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of psoriasis across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of psoriasis by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of psoriasis by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of psoriasis by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with psoriasis across the seven major markets?
• What is the size of the psoriasis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of psoriasis?
• What will be the growth rate of patients across the seven major markets?
   

Psoriasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for psoriasis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the psoriasis market?
• What are the key regulatory events related to the psoriasis market?
• What is the structure of clinical trial landscape by status related to the psoriasis market?
• What is the structure of clinical trial landscape by phase related to the psoriasis market?
• What is the structure of clinical trial landscape by route of administration related to the psoriasis market?